Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
AMGEN INC incurred credit facility.
- Instrument
- credit facility
- Event
- incurrence
Exact text from the filing
On December 12, 2022, Amgen entered into the Bridge Credit Agreement as described under Item 1.01 above.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
AMGEN INC entered into Transaction Agreement with Horizon Therapeutics plc valued at $116.50 in cash per ordinary share (effective 2022-12-11).
- Action
- entry
- Agreement
- merger
- Counterparty
- Horizon Therapeutics plc
- Value
- $116.50 in cash per ordinary share
- Effective
- 2022-12-11
Exact text from the filing
On December 12, 2022, Amgen Inc., a Delaware corporation (“ Amgen ”), issued an announcement (the “ Rule 2.7 Announcement ”) pursuant to Rule 2.7 of the Irish Takeover Panel Act 1997, Takeover Rules, 2022 (the “ Irish Takeover Rules ”) disclosing that the respective boards of directors of Amgen and Horizon Therapeutics plc, an Irish public limited company (“ Horizon ”), had reached an agreement on the terms of a cash offer for Horizon by Pillartree Limited, a newly formed private limited company wholly owned by Amgen (“ Acquirer Sub ”), pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of Horizon (such proposed offer, the “ Acquisition ”), for $116.50 in cash per ordinary share (the “ Consideration ”), nominal value $0.0001 per share, of Horizon (each, a “ Horizon Share ”).
View on SEC.gov